Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT03507374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03507374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Terminated
Start date
October 30, 2018
Completion date
April 17, 2020
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intracranial atherosclerosis, intraplaque hemorrhage, stroke